Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

JAMA

Volumn 283, Issue 1, 2000, Pages 74-80

  Sulkowski, Mark S ^a   Thomas, David L ^a,b   Chaisson, Richard E ^a,b   Moore, Richard D ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Hygiene and Public Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; INDINAVIR; NELFINAVIR; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC HEPATITIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; LIVER TOXICITY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR;

EID: 0034606721     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.283.1.74     Document Type: Article

References (44)

1. Lee BL, Safrin S. Interactions and toxicities of drugs used in patients with AIDS. Clin Infect Dis. 1992;14:773-779.
2. Zylberberg H, Pol S. Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections. Clin Infect Dis. 1996;23:1117-1125.
3. Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis. 1991;163:1138-1140.
4. Perrillo RP, Regenstein FG, Roodman ST. Chronic hepatitis B in asymptomatic homosexual men with antibody to the human immunodeficiency virus. Ann Intern Med. 1986;105:382-383.
5. Brau N, Leaf HL, Wieczorek RL, Margolis DM. Severe hepatitis in three AIDS patients treated with indinavir. Lancet 1997;349:924-925.
6. Matsuda J, Gohchi K. Severe hepatitis in patients with AIDS and haemophilia B treated with indinavir. Lancet. 1997;350:364.
7. Arribas JR, Ibanez C, Ruiz-Antoran B, et al. Acute hepatitis in HIV-infected patients during ritonavir treatment. AIDS. 1998;12:1722-1724.
8. Rodriguez-Rosado R, Garcia-Samaniego J, Soriano V. Hepatotoxicity after introduction of highly active antiretroviral therapy. AIDS. 1998;12:1256.
9. Markowitz M, Conant M, Hurley A, et al. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency (HIV)-1 protease, to treat HIV infection. J Infect Dis. 1998;177:1533-1540.
10. Lee C, Stein JJ, Kravetz JD, et al. Hepatic complications of HIV-infected individuals treated with indinavir. J Acquir Immune Defic Syndr. In press.
11. Miwa LJ, Jones JK, Pathiyal A, Hatoum H. Value of epidemiologic studies in determining the true incidence of adverse events: the nonsteroidal anti-inflammatory drug story. Arch Intern Med. 1997;157: 2129-2136.
12. Moore RD, Fortgang I, Keruly J, Chaisson RE. Adverse events from drug therapy for human immunodeficiency virus disease. Am J Med. 1996;101:34-40.
13. Moore RD, Stanton D, Gopalan R, Chaisson RE. Racial difference in the use of drug therapy for HIV disease in an urban community. N Engl J Med. 1994: 330:763-768.
14. AIDS Clinical Trials Group. Table of Grading Severity of Adult Adverse Experiences. Rockville, Md: Division of AIDS, National Institute of Allergy and Infectious Diseases; 1996.
15. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR Morb Mortal Wkly Rep. 1998;47(RR-3):38-78.
16. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med. 1996;335:1081-1090.
17. The Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet. 1996;348:283-291.
18. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet. 1997;349:1413-1421.
19. Indinavir sulfate (Crixivan) [package insert]. West Point, Pa: Merck & Co Inc; 1997.
20. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725-733.
21. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997; 337:734-739
22. Nelfinavir mesylate (Viracept) [package insert]. La Jolla, Calif: Agouron Pharmaceuticals Inc; 1997.
23. Delmas C, Szafir D, Trylesinski A, et al. Safety profile of Viracept in the treatment of HIV patients: the French compassionate use program experience. In: Abstracts from the 12th World AIDS Conference; June 28-30 and July 1-2, 1998; Geneva, Switzerland. Abstract 12393.
24. Saquinavir mesylate (Invirase) [package insert]. Nutley, NJ: Roche Laboratories Inc; 1997.
25. Saquinavir soft gelatin capsules (Fortavase) [package insert]. Nutley, NJ: Roche Laboratories Inc; 1997.
26. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med. 1996;334:1011-1018.
27. Gill MJ. Safety profile of soft gelatin formulation of saquinavir in combination with nucleosides in a broad patient population. AIDS. 1998;12:1400-1402.
28. Ritonavir (Norvir) [package insert]. Abbott Park, III: Abbott Laboratories; 1997.
29. Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet. 1998;351:543-549.
30. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease N Engl J Med. 1995;333:1528-1533.
31. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med. 1995; 333:1534-1539.
32. Cameron DW, JapourA, Mellors J, et al. Antiretroviral safety and durability of ritonavir-saquinavir in protease inhibitor naïve patients in year two of followup. In: Programs and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, III. Abstract 388.
33. Kumar GN, Rodrigues AD, Buko AM, Denissen JF. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther. 1996; 277:423-431.
34. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-F58.
35. Ungo JR, Jones D, Ashkin D, et al. Antituberculosis drug-induced hepatotoxicity: the role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med. 1998;157:1871-1876.
36. Rutschmann OT, Negro F, Hirschel B, Hadengue A, Anwar D, Perrin LH. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J Infect Dis. 1998;177:783-785.
37. Vento S, Garofano T, Renzini C, Casali F, Ferraro T, Concia E. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy. AIDS. 1998;12:116-117.
38. John M, Flexman J, French MA. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? AIDS. 1998;12:2289-2293.
39. Verdon R, Vabret A, Goubin P, et al. HIV-HCV confection: is HIV viral load decrease associated with HCV viral load variations. In: Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 24-27, 1998; San Diego, Calif. Abstract H-111.
40. Zylberberg H, Chaix M-L, Rabian C et al. Tritherapy for human immunodeficiency virus infection does not modify replication of hepatitis C virus in coinfected subjects. Clin Infect Dis. 1998;26:1104-1106.
41. Bangsberg D, Tulsky JP, Hecht FM, Moss AR. Protease inhibitors in the homeless. JAMA. 1997;278: 63-65.
42. Chaisson RE, Keruly JC, Moore RD. Race, sex, drug use, and progression of human immunodeficiency virus disease. N Engl J Med. 1995;333:751-756.
43. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:81-87.
44. Thomas DL, Rai R, Anania F, et al. A prospective investigation of hepatitis C viral load [abstract]. Hepatology. 1998;28:568.